A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Completed · Phase 1

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577 when administered alone and in combination with midazolam.

Key facts

Study ID

NCT02841761

Run by

Idorsia Pharmaceuticals Ltd.

People needed

20

Starts

2016-07-01

Expected to finish

2016-10-01

Last updated by the study team

2022-11-29

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Signed informed consent in the local language prior to any study-mandated procedure
• Body mass index (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at screening
• Healthy on the basis of medical history, physical examination, cardiovascular assessments and serology and laboratory tests

You may not qualify if…

• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Where it is running

• Investigator Site — Newark, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.